SCHEMBL4187241

SCHEMBL4187241

COc1ccc(-n2ncc3c(Nc4cc(NC(=O)c5cccc(C(F)(F)F)c5)ccc4C)ncnc32)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.57
MAPT P10636 2/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
THRB P10828 1/20 0.55
LCK P06239 2/20 0.54
DYRK3 O43781 1/20 0.54
CSF1R P07333 1/20 0.54
LYN P07948 1/20 0.54
KIT P10721 1/20 0.54
FRK P42685 1/20 0.54
PRKCD Q05655 1/20 0.54
SRPK1 Q96SB4 1/20 0.54
MAP3K20 Q9NYL2 1/20 0.54
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
ALDH1A1 P00352 1/20 0.53
GAA P10253 1/20 0.53
RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4789574 0.94 MAPK14 (0.63) MAPK14MAPTLMNATP53THRB
SCHEMBL4697666 0.92 PIP4K2A (0.53) MAPK14MAPTLMNATP53THRB
SCHEMBL4701650 0.92 MAPK14 (0.59) MAPK14MAPTLMNATP53THRB
SCHEMBL4751792 0.91 MAPK14 (0.58) MAPK14MAPTLMNATP53THRB
SCHEMBL4699789 0.91 LMNA (0.59) MAPK14MAPTLMNATP53THRB
SCHEMBL4697959 0.91 MAPK14 (0.56) MAPK14MAPTLMNATP53THRB
SCHEMBL4755211 0.90 MAPT (0.62) MAPK14MAPTLMNATP53THRB
SCHEMBL4697955 0.90 MAPK14 (0.57) MAPK14MAPTLMNATP53THRB
SCHEMBL4698956 0.90 MAPK14 (0.57) MAPK14MAPTLMNATP53LCK
SCHEMBL4919350 0.89 MAPT (0.54) MAPK14MAPTLMNATP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US claimed
EP-1963327-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS Novartis AG (CH) 2008-09-03 EP claimed
WO-2007062805-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-07 WO claimed
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders SIVASANKARAN RAJEEV 2009-03-12 US disclosed
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US disclosed
EP-1963327-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007062805-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders EPHA5, EPHA7, EPHA1 MAPK14 1758/4885MAPT 582/4885LMNA 4109/4885
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors EPHB3, EPHB2, EPHB1 MAPK14 252/4885MAPT 2142/4885LMNA 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.